RE: Featured in podcast22 Nov 2020 20:47
Here's one of his posts from August
Hi All,
here is a link to a podcast featuring Diurnal, this covers the award in the news on the 27th, plus looking at news flow. The guy interviewed owns the stock, he believes a good deal of growth, possibly September (nothing you don't know here).
Growing quickly in Europe, double digit growth.
Big news is FDA approval, expected by end September (possibly slightly after).
Medium/short term, Q1 next year, bigger approval on Chronocort, if this comes through a substantial uplift, a much larger market.
These things can still go wrong. But this is actually re-formulation of existing drugs, so balance of probability, approval should come.
He outlined the drugs use and effects, they explore the current standard of care. The difference being the dosage accuracy for Alkindi, Chronocort is all about sustained release over time. The current method is pills, the more pills the more swings (currently).
The regulatory pathway - EMA suggested they file! The EMA said there is a need for this drug.
Financials - how are they doing? They did a fundraise in June for £14m, which will fund them through to profitability. This significantly de-risks the business and all is going to plan.
There is more to the story, dialogue with Americans on Testosterone $14b market. This would be a substantial product. Again, a re-formulation of testosterone so a faster pathway.
This drug would require further financing but they aren't pushing for that yet, could come later, could be partnership.
All is positive news. Definitely in a strong position.
This is one of a few AIM companies making revenue from a drug it has developed. They have partner in US which will pay a royalty.